vs

Side-by-side financial comparison of BRINKS CO (BCO) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

BRINKS CO is the larger business by last-quarter revenue ($1.4B vs $961.0M, roughly 1.4× DENTSPLY SIRONA Inc.). BRINKS CO runs the higher net margin — 3.9% vs -15.2%, a 19.1% gap on every dollar of revenue. On growth, BRINKS CO posted the faster year-over-year revenue change (10.0% vs 6.2%). BRINKS CO produced more free cash flow last quarter ($435.5M vs $60.0M). Over the past eight quarters, BRINKS CO's revenue compounded faster (4.8% CAGR vs 0.4%).

The Brink's Company is an American cash handling company, headquartered in Richmond, Virginia. Its operations include cash-in-transit, ATM replenishment & maintenance, and cash management & payment services, such as vault outsourcing, money processing, intelligent safe services, and international transportation of valuables.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

BCO vs XRAY — Head-to-Head

Bigger by revenue
BCO
BCO
1.4× larger
BCO
$1.4B
$961.0M
XRAY
Growing faster (revenue YoY)
BCO
BCO
+3.8% gap
BCO
10.0%
6.2%
XRAY
Higher net margin
BCO
BCO
19.1% more per $
BCO
3.9%
-15.2%
XRAY
More free cash flow
BCO
BCO
$375.5M more FCF
BCO
$435.5M
$60.0M
XRAY
Faster 2-yr revenue CAGR
BCO
BCO
Annualised
BCO
4.8%
0.4%
XRAY

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
BCO
BCO
XRAY
XRAY
Revenue
$1.4B
$961.0M
Net Profit
$53.9M
$-146.0M
Gross Margin
46.1%
Operating Margin
8.0%
-14.5%
Net Margin
3.9%
-15.2%
Revenue YoY
10.0%
6.2%
Net Profit YoY
54.9%
66.0%
EPS (diluted)
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCO
BCO
XRAY
XRAY
Q2 26
$1.4B
Q4 25
$1.4B
$961.0M
Q3 25
$1.3B
$904.0M
Q2 25
$1.3B
$936.0M
Q1 25
$1.2B
$879.0M
Q4 24
$1.3B
$905.0M
Q3 24
$1.3B
$951.0M
Q2 24
$1.3B
$984.0M
Net Profit
BCO
BCO
XRAY
XRAY
Q2 26
$53.9M
Q4 25
$68.1M
$-146.0M
Q3 25
$36.3M
$-427.0M
Q2 25
$43.7M
$-45.0M
Q1 25
$51.6M
$20.0M
Q4 24
$38.5M
$-430.0M
Q3 24
$28.9M
$-494.0M
Q2 24
$46.2M
$-4.0M
Gross Margin
BCO
BCO
XRAY
XRAY
Q2 26
Q4 25
27.7%
46.1%
Q3 25
25.8%
48.8%
Q2 25
24.9%
52.4%
Q1 25
24.6%
53.0%
Q4 24
26.1%
49.3%
Q3 24
25.0%
52.1%
Q2 24
25.2%
51.9%
Operating Margin
BCO
BCO
XRAY
XRAY
Q2 26
8.0%
Q4 25
13.1%
-14.5%
Q3 25
11.4%
-24.1%
Q2 25
10.3%
-13.7%
Q1 25
9.6%
7.2%
Q4 24
8.3%
-56.2%
Q3 24
8.9%
-48.6%
Q2 24
9.3%
5.1%
Net Margin
BCO
BCO
XRAY
XRAY
Q2 26
3.9%
Q4 25
4.9%
-15.2%
Q3 25
2.7%
-47.2%
Q2 25
3.4%
-4.8%
Q1 25
4.1%
2.3%
Q4 24
3.0%
-47.5%
Q3 24
2.3%
-51.9%
Q2 24
3.7%
-0.4%
EPS (diluted)
BCO
BCO
XRAY
XRAY
Q2 26
Q4 25
$1.62
$-0.74
Q3 25
$0.86
$-2.14
Q2 25
$1.03
$-0.22
Q1 25
$1.18
$0.10
Q4 24
$0.87
$-2.09
Q3 24
$0.65
$-2.46
Q2 24
$1.02
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCO
BCO
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$1.7B
$326.0M
Total DebtLower is stronger
$4.1B
$2.3B
Stockholders' EquityBook value
$407.3M
$1.3B
Total Assets
$7.3B
$5.4B
Debt / EquityLower = less leverage
9.95×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCO
BCO
XRAY
XRAY
Q2 26
$1.7B
Q4 25
$1.7B
$326.0M
Q3 25
$1.3B
$363.0M
Q2 25
$1.4B
$359.0M
Q1 25
$1.2B
$398.0M
Q4 24
$1.4B
$272.0M
Q3 24
$1.2B
$296.0M
Q2 24
$1.2B
$279.0M
Total Debt
BCO
BCO
XRAY
XRAY
Q2 26
$4.1B
Q4 25
$4.0B
$2.3B
Q3 25
$3.8B
Q2 25
$3.9B
Q1 25
$3.7B
Q4 24
$3.7B
$1.7B
Q3 24
$3.7B
Q2 24
$3.6B
Stockholders' Equity
BCO
BCO
XRAY
XRAY
Q2 26
$407.3M
Q4 25
$277.7M
$1.3B
Q3 25
$268.5M
$1.5B
Q2 25
$254.6M
$2.0B
Q1 25
$205.8M
$2.0B
Q4 24
$184.9M
$1.9B
Q3 24
$277.1M
$2.5B
Q2 24
$320.5M
$3.1B
Total Assets
BCO
BCO
XRAY
XRAY
Q2 26
$7.3B
Q4 25
$7.3B
$5.4B
Q3 25
$7.0B
$5.7B
Q2 25
$7.1B
$6.1B
Q1 25
$6.6B
$6.0B
Q4 24
$6.6B
$5.8B
Q3 24
$6.7B
$6.6B
Q2 24
$6.6B
$6.9B
Debt / Equity
BCO
BCO
XRAY
XRAY
Q2 26
9.95×
Q4 25
14.31×
1.70×
Q3 25
14.05×
Q2 25
15.48×
Q1 25
18.19×
Q4 24
20.26×
0.90×
Q3 24
13.39×
Q2 24
11.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCO
BCO
XRAY
XRAY
Operating Cash FlowLast quarter
$101.0M
Free Cash FlowOCF − Capex
$435.5M
$60.0M
FCF MarginFCF / Revenue
31.7%
6.2%
Capex IntensityCapex / Revenue
4.3%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCO
BCO
XRAY
XRAY
Q2 26
Q4 25
$101.0M
Q3 25
$122.1M
$79.0M
Q2 25
$48.0M
Q1 25
$-60.2M
$7.0M
Q4 24
$369.8M
$87.0M
Q3 24
$58.4M
$141.0M
Q2 24
$-66.1M
$208.0M
Free Cash Flow
BCO
BCO
XRAY
XRAY
Q2 26
$435.5M
Q4 25
$60.0M
Q3 25
$77.4M
$40.0M
Q2 25
$16.0M
Q1 25
$-119.1M
$-12.0M
Q4 24
$307.2M
$36.0M
Q3 24
$7.4M
$98.0M
Q2 24
$-122.8M
$156.0M
FCF Margin
BCO
BCO
XRAY
XRAY
Q2 26
31.7%
Q4 25
6.2%
Q3 25
5.8%
4.4%
Q2 25
1.7%
Q1 25
-9.6%
-1.4%
Q4 24
24.3%
4.0%
Q3 24
0.6%
10.3%
Q2 24
-9.8%
15.9%
Capex Intensity
BCO
BCO
XRAY
XRAY
Q2 26
4.3%
Q4 25
3.5%
4.3%
Q3 25
3.3%
4.3%
Q2 25
4.0%
3.4%
Q1 25
4.7%
2.2%
Q4 24
5.0%
5.6%
Q3 24
4.1%
4.5%
Q2 24
4.5%
5.3%
Cash Conversion
BCO
BCO
XRAY
XRAY
Q2 26
Q4 25
Q3 25
3.36×
Q2 25
Q1 25
-1.17×
0.35×
Q4 24
9.61×
Q3 24
2.02×
Q2 24
-1.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCO
BCO

North America$418.0M30%
Europe$319.0M23%
Latin America$308.0M22%
Rest of World$203.0M15%
Other$127.0M9%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons